New Targets for the Treatment of Hypertension and Associated Diseases

1st Edition, Volume 94 - June 2, 2022
Latest edition
Editors: William B. Campbell, John D. Imig
Language: English

New Targets for the Treatment of Hypertension and Associated Diseases, Volume 94 in the Advances in Pharmacology serial, highlights new advances in the field, with this new volu… Read more

WINTER SALE

Discover your season of innovation

Up to 25% off books, eBooks and Journals

Shop now

New Targets for the Treatment of Hypertension and Associated Diseases, Volume 94 in the Advances in Pharmacology serial, highlights new advances in the field, with this new volume presenting interesting chapters on Cytochrome P450, 20-hydroxyeicosatetraenoic acid and GPR75 pathway in hypertension, Treatment of hypertension with soluble epoxide hydrolase inhibitors, Effects of allosteric modifiers of adenosine receptors in the heart, Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury, Drugs affecting the nitric oxide- cyclic GMP pathway in hypertension, Relaxin-2 and Serelaxin in renal and cardiac dysfunction in hypertension, and more.

William B. Campbell

William B. Campbell, PhD, Professor and Chairman of the Department of Pharmacology and Toxicology at the Medical College of Wisconsin received his PhD from the University of Texas Health Science Center in Dallas. After post-doctoral work and another year as an instructor at the Medical College of Wisconsin he moved to the Department of Pharmacology at the University of Texas Southwestern Medical Center where he would eventually become full Professor of Pharmacology. In 1992 he became Chair of Pharmacology at the Medical College of Wisconsin. For the past 30 years, Dr. Campbell has been investigating the contribution of various vasoactive agents that regulate blood pressure. His studies on endothelium-derived factors that regulate blood pressure and vascular tone identified the major vasoactive metabolites of arachidonic acid that are produced by the vascular endothelium. He has consistently made major contributions in research, teaching and service to various institutions and to the scientific community in general. Dr. Campbell has received numerous awards for his research including the Research Career Development Award from the National Institutes of Health. In 2006, he received the Novartis Award for Hypertension Research, the most prestigious award in the world in the area of hypertension research. He has received the Outstanding Mentor and Teaching Award from the Medical College of Wisconsin.

Affiliations and expertise

Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, USA

John D. Imig

John D. Imig, Ph.D. is a Professor and Director Drug Discovery at the Medical College of Wisconsin. Dr. Imig has received a number of awards for his research in cardiovascular and renal physiology included the prestigious Established Investigator Award from the American Heart Association. Dr. Imig has authored over 200 publications related to the antihypertensive properties and renal and cardiovascular protective properties of angiotensin receptor antagonists and soluble epoxide hydrolase inhibitors.

Affiliations and expertise

Drug Discovery Center, Medical College of Wisconsin, Milwaukee, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

New Targets for the Treatment of Hypertension and Associated Diseases

Discover your season of innovation

Description

Key features

Readership

Table of contents

Product details

About the editors

William B. Campbell

John D. Imig

View book on ScienceDirect